

Workshops on Immunopathological Diseases and Therapeutics



Ecole Pratique des Hautes Etudes
INSERM, University of Burgundy



UCLA
Jonsson Comprehensive Cancer Center

Second International Workshop on “Nitric Oxide in Cancer Therapy”

September 11-12, 2009

Dijon, France

Co-Chairs

Jean-François Jeannin (France)
Benjamin Bonavida (USA)

Local Organizers

Jean-François Jeannin
Ali Bettaieb
Catherine Paul

Friday September 11	
9:00 am – 9:15 am	General Introduction
	J.F. Jeannin and B. Bonavida
9:15 am – 12:00 am	Session 1: Overview of the field
	Chairs: S Moncada, University College, London, U.K.; D. Wink, National Cancer Institute, Bethesda, USA
9:15 am – 10:00 am	S. Moncada, University College, London, U.K.
10:00 am – 10:45 am	D. Wink, National Cancer Institute, Bethesda, USA
10:45 am – 11:15 am	Coffee break
11:15 am – 11:45 am	D. Geller, University of Pittsburgh, USA
11:45 am – 12:15 pm	Roundtable discussion and concluding remarks, S. Moncada, D. Wink, D. Geller, J. Lancaster.
12:15 pm – 14:00 pm	Lunch
14:00 pm – 16:30 pm	Session 2: General approaches to induce/deliver therapeutic levels of NO
	Chairs: D.G. Hirst, Belfast Queen's University, UK; G. Thatcher, University of Illinois, Chicago, USA
14:00 pm - 14:30 pm	L. Keefer, National Cancer Institute, Bethesda, USA
14:30 pm - 15:00 pm	J. Lancaster, University of Alabama, Birmingham, USA
15:00 pm - 15:30 pm	G. Thatcher, University of Illinois, Chicago, USA
15:30 pm - 16:00 pm	D.G. Hirst, Belfast Queen's University, UK

16:00 pm - 16:30 pm	Roundtable discussion and concluding remarks, L. Keefer, J. Lancaster, G. Thatcher, D.G. Hirst, S Moncada
16:30 pm - 17:00 pm	Coffee break
17:00 pm – 19:00 pm	Session 3: Young Investigators' Oral Presentations
	Chairs: M. Lepoivre, CNRS, Orsay, France; A Bettaieb, EPHE/INSERM, Dijon, France
17:00 pm – 17:20 pm	S. Baritaki, University of California, Los Angeles, USA
17:20 pm – 17:40 pm	S. Huerta, University of Texas, Dallas, USA
17:40 pm – 18:00 pm	L. Léon, EPHE/INSERM, Dijon, France
18:00 pm – 18:20 pm	H. Garban, University of California, Los Angeles/Harbor, USA
18:20 pm - 18:40 pm	M Cortier, EPHE/INSERM, Dijon, France
18:40 pm - 19:00 pm	Roundtable discussion, M. Lepoivre, A. Bettaieb, Z. Atassi
20:00 pm	Gala Dinner
Saturday September 12	
9:00 am – 12:30 pm	Session 4: NO and chemo-, immuno and radio-therapy in preclinical models
	Chairs: S. Chouaib, INSERM, Villejuif, France ; D. Spandidos, University of Crete, Greece
9:00 am – 9:30 am	J.F. Jeannin, EPHE/INSERM, Dijon, France
9:30 am – 10:00 am	C.H. Graham, Queen's University, Kingston, Canada
10:00 am – 10:30 am	O. Féron, Université catholique de Louvain, Brussels, Belgium
10:30 am – 11:00 am	Coffee break
11:00 am – 11:30 am	B. Bonavida, UCLA, Los Angeles, USA
11:30 am – 12:00 am	M. De Ridder, Oncologisch Centrum, Brussels, Belgium
12:00 am - 12:30 pm	Roundtable discussion and concluding remarks, J.F. Jeannin, G.H. Graham, O. Féron, B. Bonavida, M. De Rider, S. Chouaib, D. Spandidos, D. Wink
12:30 am – 14:00 pm	Lunch
14:00 pm – 16:00 pm	Session 5: Clinical application of NO in human cancers
	Chair: M. Bardou, University Hospital, Dijon, France, F. Nicoletti, University of Catania, Italy
14:00 pm - 14:30 pm	D.R. Siemens, Queen's University, Kingston, Canada
14:30 pm - 15:00 pm	H. Yasuda, Kyoto University Hospital, Japan
15:00 pm – 16:00 pm	Roundtable discussions and concluding remarks, D.R. Siemens, H. Yasuda, M. Bardou, F. Nicoletti, S. Chouaib
16:00 pm - 16:30 pm	Coffee break and adjournment
16:30 pm – 18:00 pm	Session 6: Tutorials
	Chairs: J.F. Jeannin, EPHE/INSERM, Dijon, France; J. Lancaster, University of Alabama, Birmingham, USA

Speakers

Baritaki S., *UCLA, Los Angeles, USA*
Bonavida B., *UCLA, Los Angeles, USA*
Cortier M., *EPHE/INSERM, Dijon, France*
De Ridder M., *Oncologisch Centrum, Belgium*
Féron O., *Univ. Catholique de Louvain, Belgium*
Garban H., *UCLA / Harbor, USA*
Geller D., *University of Pittsburgh, USA*
Graham C.H., *Queen's University, Kingston, Canada*
Hirst D.G. , *Belfast Queen's University, UK*
Huerta S., *University of Texas, Dallas, USA*
Jeannin J.F., *EPHE/INSERM, Dijon, France*
Keefer L., *National Cancer Institute, Bethesda, USA*
Lancaster J., *University of Alabama, USA*
Léon L., *EPHE/INSERM, Dijon, France*
Moncada S., *University College, London, U.K.*
Siemens D.R., *Queen's University, Kingston, Canada*
Thatcher G., *University of Illinois, Chicago, USA*
Wink D., *National Cancer Institute, Bethesda, USA*
Yasuda H., *Kyoto University Hospital, Japan*

Chairs

Bardou M., *University Hospital, Dijon, France*
Bettaieb A., *EPHE, INSERM, Dijon, France*
Chouaib S., *INSERM, Villejuif, France*
Hirst D.G. , *Belfast Queen's University, UK*
Lancaster, *University of Alabama, Birmingham, USA*
Lepoivre M., *CNRS, Orsay, France*
Moncada S., *University College, London, U.K.*
Nicoletti F., *University of Catania, Italy*
Spandidos D., *University of Crete, Greece*
Thatcher G., *University of Illinois, Chicago, USA*
Wink D., *National Cancer Institute, Bethesda, USA*

Discussants

Atassi, Z., *Baylor University, Houston, Texas*
Bardou M., *University Hospital, Dijon, France*
Bettaieb A., *EPHE, INSERM, Dijon, France*
Chouaib S., *INSERM, Villejuif, France*
De Ridder M., *Oncologisch Centrum, Belgium*
Hirst D.G. , *Belfast Queen's University, UK*
Keefer L., *National Cancer Institute, Bethesda, USA*
Lancaster J., *University of Alabama, USA*
Lepoivre M., *CNRS, Orsay, France*
Moncada S., *University College, London, U.K.*
Nicoletti, F., *Catania University, Catania, Italy*
Spandidos D., *University of Crete, Greece*
Thatcher G., *University of Illinois, Chicago, USA*
Wink D., *National Cancer Institute, Bethesda, USA*